Alnylam Pharmaceuticals (ALNY) Stock Price, Quote & News

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products i...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 551 8200

Fax: 617 551 8101

Website: www.alnylam.com

Address:

675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States

chartistmind Aug. 4 at 6:52 PM

$ALNY

0 · Reply

sampeper Aug. 4 at 5:34 PM

$ALNY Looks like it wants to explod 🫠 Shorti mus cover now!

0 · Reply

anachartanalyst Aug. 4 at 4:02 PM

$ALNY https://anachart.com/wp-content/uploads/2026/08/1785859316_soc-img.jpg

0 · Reply

sampeper Aug. 4 at 1:45 PM

$ALNY mega short sequence will start any time 🫠 🫠

0 · Reply

sampeper Aug. 3 at 11:27 PM

$ALNY ALNY Maintained by Barclays -- Price Target Lowered to $450 https://www.gurufocus.com/news/8998044/alny-maintained-by-barclays-price-target-lowered-to-450#google_vignette

0 · Reply

sampeper Aug. 3 at 11:26 PM

$ALNY Citi Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $340 https://www.moomoo.com/news/post/73988009/citi-maintains-alnylam-pharmaceuticals-alnyus-with-buy-rating-cuts-target?level=1&data_ticket=1776416983151450

0 · Reply

bitra Aug. 3 at 10:40 PM

$ALNY $600 price target

0 · Reply

moneybag888 Aug. 3 at 3:25 PM

$JAZZ deja vu $ALNY

0 · Reply

sampeper Aug. 3 at 3:21 PM

$ALNY Looks like it wants to explod

0 · Reply

PeterBrenneman862 Aug. 3 at 3:14 PM

$ATO $TS $FTS $MTD $ALNY Atmos Energy provides dependable utility income, Tenaris benefits from energy infrastructure, Fortis delivers regulated utility stability, Mettler-Toledo leads precision instruments, and Alnylam advances RNA therapeutics.

0 · Reply

Alnylam price target lowered to $455 from $485 at H.C. Wainwright

2026-08-04T11:25:27.000Z - 12 hours ago

Alnylam price target lowered to $315 from $410 at Truist

Aug 3, 2026, 6:20 PM EDT - 1 day ago

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

2026-08-03T11:26:02.000Z - 1 day ago

Alnylam upgraded to Strong Buy from Outperform at Raymond James

2026-08-03T10:31:12.000Z - 1 day ago

Alnylam price target lowered to $340 from $380 at Citi

2026-08-03T09:20:32.000Z - 1 day ago

Alnylam price target lowered to $450 from $527 at Barclays

2026-07-31T12:46:57.000Z - 4 days ago

Alnylam price target lowered to $346 from $410 at BofA

2026-07-31T12:36:26.000Z - 4 days ago

Alnylam price target lowered to $420 from $468 at Raymond James

2026-07-31T12:01:23.000Z - 4 days ago

Alnylam price target lowered to $350 from $500 at Oppenheimer

2026-07-31T11:56:22.000Z - 4 days ago

Alnylam price target lowered to $375 from $400 at JPMorgan

2026-07-31T11:56:10.000Z - 4 days ago

Alnylam price target lowered to $300 from $400 at Morgan Stanley

2026-07-31T11:22:07.000Z - 4 days ago

Alnylam price target lowered to $318 from $444 at Stifel

2026-07-30T16:05:45.000Z - 5 days ago

Alnylam falls -27.8%

2026-07-30T14:00:39.000Z - 5 days ago

Alnylam falls -25.5%

Jul 30, 2026, 8:30 AM EDT - 5 days ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 5 days ago

Alnylam Pharmaceuticals Earnings release: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 5 days ago

Alnylam Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 5 days ago

Alnylam Pharmaceuticals Slides: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 5 days ago

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

2026-07-22T11:25:19.000Z - 13 days ago

Alnylam price target lowered to $400 from $420 at JPMorgan

Jul 16, 2026, 8:00 AM EDT - 19 days ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Jul 15, 2026, 3:30 AM EDT - 20 days ago

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

2026-07-14T12:21:04.000Z - 21 days ago

Alnylam price target lowered to $410 from $460 at BofA

2026-07-13T14:50:11.000Z - 22 days ago

Alnylam price target raised to $485 from $470 at H.C. Wainwright

AZN IONS

Jul 9, 2026, 7:38 AM EDT - 26 days ago

AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.

AZN IONS

Jun 25, 2026, 11:00 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals Transcript: Study update

Jun 25, 2026, 11:00 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals Slides: Study update

Jun 25, 2026, 9:00 AM EDT - 5 weeks ago

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

Jun 17, 2026, 12:30 PM EDT - 6 weeks ago

The Healthcare M&A Wave

ABT AMGN AMRX ANTX AZN BDX BEAM

Jun 12, 2026, 9:00 AM EDT - 7 weeks ago

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Jun 10, 2026, 7:47 AM EDT - 7 weeks ago

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Jun 9, 2026, 11:20 AM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 5:06 PM EDT - 2 months ago

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500

ALAB BE RDDT

Jun 3, 2026, 6:05 PM EDT - 2 months ago

Alnylam, Inceptive sign up to $2 billion AI drug discovery deal

Jun 3, 2026, 4:45 PM EDT - 2 months ago

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

May 20, 2026, 10:30 AM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: AGM 2026

May 19, 2026, 8:30 AM EDT - 2 months ago

Alnylam Issues 2025 Corporate Responsibility Report

May 13, 2026, 1:40 PM EDT - 2 months ago

Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:30 AM EDT - 3 months ago

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

May 7, 2026, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Presentations at Upcoming Investor Conferences

May 4, 2026, 8:30 AM EDT - 3 months ago

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Alnylam Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Apr 6, 2026, 2:14 PM EDT - 4 months ago

An S&P 500 change may be imminent. These stocks are leading contenders to join the index.

IVV SPXL SPY SSO UPRO VOO FERG

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Alnylam Pharmaceuticals Proxy statement: Proxy filing

Mar 30, 2026, 1:00 PM EDT - 4 months ago

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Mar 24, 2026, 9:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Transcript: Status update

Mar 24, 2026, 9:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Press release: Status update

Mar 24, 2026, 9:30 AM EDT - 4 months ago

Alnylam Pharmaceuticals Slides: Status update

Mar 24, 2026, 9:00 AM EDT - 4 months ago

Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis

Mar 24, 2026, 7:30 AM EDT - 4 months ago

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

Mar 11, 2026, 11:55 AM EDT - 5 months ago

How Alnylam Stock Weathers Market Shocks

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Alnylam to Webcast TTR Investor Webinar

Mar 5, 2026, 9:10 AM EST - 5 months ago

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

TNYA

Mar 5, 2026, 8:30 AM EST - 5 months ago

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

TNYA

Mar 2, 2026, 9:10 AM EST - 5 months ago